irritable bowel syndrome

[Immunic Therapeutics Inc.] Immunic, Inc.announced dosing of the first healthy volunteer in the company’s phase I clinical program of IMU-856, an orally available, small molecule modulator that targets a yet undisclosed protein which serves as a transcriptional regulator of intestinal barrier function.

[Cell Proliferation] In vitro, glial cell‐derived neurotrophic factor (GDNF) treatment amplified Wnt signal and increased serotonin levels in colonic organoids in a dose‐dependent manner.

[International Journal of Molecular Sciences] The authors provide an update on the literature to understand how genetics, diet, and the gut microbiota influence the crosstalk between immune and non-immune cells resulting in inflammation observed in multiple colonic pathologies.